logo-loader
Poolbeg Pharma PLC

Interim data from POLB 001 TOPICAL clinical trial

RNS Number : 0531W
Poolbeg Pharma PLC
24 September 2026
 


 

Poolbeg Pharma plc

 

Interim data from POLB 001 TOPICAL clinical trial

Positive interim review marks key milestone for POLB 001 clinical development

 

24 September 2026 - Poolbeg Pharma (AIM: POLB, 'Poolbeg' or the 'Company'), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces that the ongoing TOPICAL clinical trial will proceed as planned following a positive review of data from the interim safety cohort. The completion of this review represents an important milestone for the TOPICAL trial.

 

The review recommended that the trial continue as planned, with no changes required to the study protocol. Patient recruitment is continuing across leading UK clinical sites, with further patients expected to be enrolled and additional sites activated.

 

The Company looks forward to generating further data and sharing more detail with prospective partners. Bispecific antibodies are becoming increasingly important in the treatment of cancer, and an effective CRS preventative therapy could represent an important advance for patients, clinicians and healthcare systems.

 

Jeremy Skillington, PhD, Chief Executive Officer of Poolbeg Pharma, said: “The data from the interim cohort represent a significant milestone for the TOPICAL trial. The positive recommendation to continue the study as planned provides further confidence as we advance the POLB 001 programme.

 

“We are building momentum across the study, with recruitment continuing at leading UK clinical sites, further patients expected to be enrolled and additional sites activated. We look forward to generating further clinical data and sharing more detail with prospective partners as we continue discussions around the POLB 001 opportunity.”

 

Investor presentation

Poolbeg Pharma will provide a live presentation via the Investor Meet Company platform today, 24 September 2026 at 2:00pm.

 

The presentation is open to analysts and investors, those who already follow Poolbeg on the Investor Meet Company platform will automatically be invited. Investors can sign up to Investor Meet for free and add Poolbeg Pharma plc to their company dashboard here.

 

 The TOPICAL trial is evaluating POLB 001 as a preventative therapy for Cytokine Release Syndrome (“CRS”) in patients with relapsed/refractory multiple myeloma receiving the approved bispecific antibody teclistamab.

 

Enquiries  

Poolbeg Pharma Plc  

Jeremy Skillington, CEO  

Ian O'Connell, CFO  

   

+44 (0) 207 183 1499 

ir@poolbegpharma.com 

Cavendish Capital Markets Ltd (NOMAD & Joint Broker)  

Geoff Nash, Trisyia Jamaludin (Corporate Finance) 

Nigel Birks (Life Science Specialist Sales) 

Harriet Ward (ECM)  

   

+44 (0) 207 220 0500  

Oak Securities (Joint Broker) 

Jerry Keen, Henry Poole

+44 (0) 20 3973 3678 

 

Shore Capital Stockbrokers Ltd (Joint Broker) 

David Coaten, Harry Davies-Ball (Corporate Advisory) 
Malachy McEntyre (Corporate Broking) 

  

+44 (0) 207 408 4090 

J&E Davy (Joint Broker)  

Anthony Farrell, Niall Gilchrist 

   

+353 (0) 1 679 6363  

Optimum Strategic Communications  

Nick Bastin, Katie Flint, Henry Williams 

   

+44 (0) 208 078 4357  

poolbeg@optimumcomms.com 

 

About Poolbeg Pharma plc

Poolbeg Pharma plc (AIM: POLB) is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company’s lead asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity. Poolbeg is also advancing the development of a patient-friendly therapy for obesity with an oral encapsulated GLP-1, offering a differentiated approach within one of the world’s largest markets. With multiple near-term clinical value inflection points, and an experienced team with a proven track record, Poolbeg is focussed on partnering its high value programmes that are targeting large markets and addressing critical unmet medical needs. 

 

Stay updated: Website | Sign up for RNS alerts | Presentation | X | LinkedIn

 

Forward-Looking Statements

This announcement may contain forward-looking statements and the words "expect", "anticipate", "intends", "plan", "estimate", "aim", "forecast", "project" and similar expressions (or their negative) identify certain of these forward-looking statements. The forward-looking statements in this announcement are based on numerous assumptions and Poolbeg's present and future business strategies and the environment in which Poolbeg expects to operate in the future. Forward-looking statements involve inherent known and unknown risks, uncertainties and contingencies because they relate to events and depend on circumstances that may or may not occur in the future and may cause the actual results, performance or achievements to be materially different from those expressed or implied by such forward-looking statements. These statements are not guarantees of future performance or the ability to identify and consummate investments. Many of these risks and uncertainties relate to factors that are beyond Poolbeg's ability to control or estimate precisely, such as future market conditions, currency fluctuations, the behaviour of other market participants, the outcome of clinical trials, the actions of regulators and other factors such as Poolbeg's ability to obtain financing, changes in the political, social and regulatory framework in which Poolbeg operates or in economic, technological or consumer trends or conditions. Past performance should not be taken as an indication or guarantee of future results, and no representation or warranty, express or implied, is made regarding future performance. No person is under any obligation to update or keep current the information contained in this announcement or to provide the recipient of it with access to any additional relevant information.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCZZGZLVFNGVZM
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not registered in any category of registration under the securities legislation of any province or territory of Canada. Nothing in this record constitutes "advice" concerning investing in, buying, or selling a security within the meaning of applicable Canadian securities legislation. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after obtaining advice from a registrant authorised under the securities legislation of your province or territory.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship is for news distribution and media services only and does not determine, influence, or shape the editorial content produced.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

Poolbeg Pharma "continuing its campaign to find a partner" for POLB001

Proactive Research Analyst Daniel Appiah speaks to Thomas Warner at the London Studio after publishing a new research note on clinical-stage biopharmaceutical company Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF). Appiah starts by explaining the scale of the opportunity that Poolbeg is pursuing...

on 2/11/23

5 min read